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ABSTRACT
Bevacizumab is currently approved in association 
with first- and second-line 5-fluorouracil–based 
chemotherapy regimens for patients with metastatic 
colorectal cancer. Few data about the usefulness of 
bevacizumab in third-line settings are available. We 
describe a patient refractory to f o l f i r i and f o l f o x  
chemotherapy regimens who showed a dramatic and 
durable response to bevacizumab and f o l f i r i. We also 
review and discuss the available literature.
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1.  INTRODUCTION
Colorectal cancer (c r c ) is the third most common 
malignancy affecting men and women in Canada 1. 
Many patients present with metastatic disease, and 
a significant proportion of those treated with cure-
intended surgery, with or without adjuvant chemo-
therapy, eventually relapse 2.
Significant improvement in chemotherapy for 
metastatic colorectal cancer (mc r c ) has been achieved 
with the addition of irinotecan and oxaliplatin to 
5-fluorouracil (5f u)–based therapy 3–5. More recently, 
targeted agents such as bevacizumab, cetuximab, and 
panitumumab have shown promising results, especially 
in combination with conventional chemotherapy 6–13.
Bevacizumab is a human recombinant monoclonal 
antibody directed against the vascular endothelial 
growth factor. Combined with 5f u-based regimens, 
bevacizumab has been shown to improve outcome in 
the setting of first- and second-line chemotherapy 10–12, 
and it is now considered a standard of care for patients 
in those settings 12. data concerning the usefulness 
of bevacizumab in the third-line treatment of mc r c  
are limited 14–17.
Here, we report on a patient diagnosed with mc r c  
who progressed after the usual f o l f i r i and f o l f o x 
regimens, but who achieved a significant tumour response 
with bevacizumab-containing third-line treatment.
2.  CASE REPORT
a 49-year-old man with an unremarkable medical his-
tory was diagnosed with metastatic cecal adenocarci-
noma in June 2005. The tumour was invading the right 
iliac fossa up to the superficial abdominal wall. This 
patient underwent extensive right hemicolectomy 
with partial abdominal wall resection on June 21. 
Pathology studies revealed a 7×8-cm infiltrative 
grade iii mucinous adenocarcinoma. Of the 36 lymph 
nodes collected, 7 were infiltrated, and some showed 
capsular rupture. lymphatic vascular permeation and 
a peritumoural metastatic peritoneal implant were 
present. The right lateral resection margin was posi-
tive. Serum carcinoembryonic antigen (c e a) dropped 
to 8.7 µg/l from 97.4 µg/l after surgery.
After a significant delay because of postoperative 
recovery and wound healing, combined positron-
emission tomography (p e t)–computed tomography 
(c t ) and contrast-enhanced c t  imaging in September 
2005 in advance of chemotherapy showed a 15-mm 
hypermetabolic subcutaneous mass in the right axil-
lary region and multiple metastatic lymph nodes and 
peritoneal implants. The patient received 12 cycles 
of f o l f i r i, given every 2 weeks from October 2005 
to March 2006. a combined p e t–c t  imaging study in 
april 2006 showed reduced metabolic activity, but 
stable disease according to the response Evaluation 
Criteria in Solid Tumors (r e c i s t ) guidelines 18. a 
small chemotherapy pause was authorized; however, 
serum c e a  rapidly rose over the subsequent weeks, 
and p e t–c t  imaging in June 2006 demonstrated dis-
ease progression with 2 new intra-abdominal lesions, 
1 along the psoas muscle and 1 along the right hepatic 
artery. Second-line chemotherapy with 8 cycles of 
f o l f o x 6 was given every 2 weeks from June to Sep-
tember 2006. Serum c e a  declined slightly after the 
first 3 cycles and then rose again under chemotherapy 
(to 16 µg/L from 23.5 µg/L, and then to 29 µg/L). A 85
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control p e t–c t  study in October 2006 demonstrated 
further disease progression of the right psoas muscle 
mass up to 4 cm.
For patient convenience, and also because of an 
early oxaliplatin-attributed sensory neuropathy, a 
switch was made to oral capecitabine 1250 mg/m2 
twice daily for 14 days every 3 weeks. In March 
2007, the p e t–c t  showed tumour progression, and 
serum c e a  was rising to 139 µg/l, but the patient 
was asymptomatic, and capecitabine was main-
tained. Control imaging in September 2007 revealed 
further enlargement of the known lesions and new 
psoas and peritoneal masses. The patient was expe-
riencing right groin pain necessitating continuous 
opioid-based analgesia, together with limited right 
hip mobility. Serum c e a  continued to rise, reaching 
a high of 552 µg/l.
Capecitabine was stopped, and the patient re-
ceived two courses of palliative radiotherapy (20 Gy 
in 5 fractions each time) in September and December 
2007 for right groin and flank pain and reduced func-
tional capacity.
In February 2008, awaiting bevacizumab ap-
proval, the patient received 2 cycles of f o l f i r i, 
without significant clinical improvement. He then 
received 10 cycles of bevacizumab (5 mg/kg) every 
2 weeks in addition to f o l f i r i. Post-treatment evalu-
ation showed near-normal functional capacity. The 
pain had resolved, and the patient was no longer 
taking analgesics. Serum c e a dropped markedly 
to 24 µg/l, and new p e t–c t  imaging showed di-
minished metabolic activity and reduced sizes of 
most of the lymph nodes and metastatic implants, 
qualifying for a partial response according to r e c i s t  
criteria (Figure 1).
at November 2008, the patient was still on 
treatment, asymptomatic and in good general and 
functional status.
3.  DISCUSSION AND CONCLUSIONS
Currently, seven chemotherapy drugs have been 
approved for patients with mc r c : 5f u, capecitabine, 
irinotecan, oxaliplatin, bevacizumab, cetuximab, and 
panitumumab. In the 1980s, 5f u was the only active 
drug for mc r c, and the addition of irinotecan and 
oxaliplatin improved response rate (r r ), progression-
free survival (p f s), and overall survival (o s ). A similar 
scenario is happening with targeted agents that are 
already showing benefits and promising results.
Bevacizumab was the first targeted agent to be 
approved for routine use in mc r c . Most clinical trials 
so far have evaluated bevacizumab in the first- and 
second-line settings, and data concerning its efficacy 
in third-line settings are scarce. The U.S. National 
Cancer Institute’s Treatment referral Center Trial by 
Chen et al. reported low r r s for third-line therapies 
using bevacizumab 14. Based on an assessment by 
the investigators, the r r  was 4%, but an independ-
ent review evaluated the rate at 1%. The p f s was 
3.5 months, and the o s  was 9 months. another trial 
presented by Emmanouilides et al. concluded that 
bevacizumab could result in disease stabilization 
and clinical benefit in a proportion of heavily pre-
treated patients, with a median time to progression 
of 16 weeks 15. The use and benefits of bevacizumab 
in salvage therapy for pretreated patients with re-
fractory c r c  are still unclear and must be assessed in 
randomized studies.
In June 2008, Shitara et al. reported on the effi-
cacy and feasibility of bevacizumab-containing third-
line chemotherapy in a patient with mc r c  that had 
progressed under f o l f o x  and f o l f i r i chemotherapy 
regimens 16. Similarly, a retrospective analysis of 
mc r c  patients pretreated with f o l f i r i and f o l f o x  and 
receiving salvage bevacizumab plus either f o l f i r i or 
f o l f o x  demonstrated a r r  of 9.5%. The median p f s and 
o s  were 5.3 months and 9.5 months respectively 17.
Our data accords with the three latter reports. 
Our patient initially presented stable disease and 
then rapid tumour progression after first-line f o l f i r i 
chemotherapy, and despite further tumour progres-
sion under f o l f o x  and capecitabine chemotherapy, he 
presented spectacular clinical improvement, reduction 
of tumour markers, and partial response on c t  scan 
under bevacizumab–f o l f i r i third-line chemotherapy. 
all these data underline the potential role of bevaci-
zumab-containing chemotherapy beyond second-line 
treatment, especially for patients who did not receive 
bevacizumab-containing first- or second-line chemo-
therapy. In such patients, the utility of bevacizumab-
containing third-line therapy should be considered.
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